<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inflammatory processes, including, specifically, the inflammatory conditions <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD) and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) predispose to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Interleukin-23 is involved in pro-inflammatory signaling; genetic variation in the interleukin-23 receptor (IL23R) has been consistently associated with CD and UC risk </plain></SENT>
<SENT sid="2" pm="."><plain>In three case-control studies of colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> (n=485 cases/578 controls), <z:hpo ids='HP_0003003'>colon cancer</z:hpo> (n=1424 cases/1780 controls) and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> (n=583 cases/775 controls), we investigated associations with 18 candidate and tagSNPs in IL23R </plain></SENT>
<SENT sid="3" pm="."><plain>The three studies used an identical Illumina GoldenGate assay, allowing thorough investigation across stages and locations of colorectal <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We further explored associations with molecular <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> subtypes (MSI+, CIMP+, KRAS2mut, TP53mut) </plain></SENT>
<SENT sid="5" pm="."><plain>In this comprehensive study of genetic variability in IL23R across the spectrum of colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, as well as within colon and <z:e sem="disease" ids="C1527408,C0034885" disease_type="Disease or Syndrome;Neoplastic Process" abbrv="">rectal tumor</z:e> molecular subtypes, we observed associations between SNPs in IL23R and risk of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>: the 88413 C&gt;A (rs10889675) and 69450 C&gt;A (rs7542081) polymorphisms were associated with decreased <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> risk overall (p-trend=0.04 and 0.05 respectively), and specifically with <z:e sem="disease" ids="C1527408,C0034885" disease_type="Disease or Syndrome;Neoplastic Process" abbrv="">rectal tumors</z:e> bearing a TP53 mutation (88413 CA/AA vs. CC OR: 0.66; 95% CI: 0.46-94; 69450 CA/AA vs. CC OR: 0.60; 95% CI: 0.37-0.98) </plain></SENT>
<SENT sid="6" pm="."><plain>However, none of associations remained statistically significant after correction for multiple testing </plain></SENT>
<SENT sid="7" pm="."><plain>These data provide some evidence that genetic variability in IL23R may contribute to <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> risk and should be evaluated in additional studies </plain></SENT>
</text></document>